Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention

References

• DaviGPatronoCPlatelet activation and atherothrombosisN Engl J Med2007357242482249418077812
   PubMed Web of Science ®Google Scholar
• KingSB3rdSmithSCJrHirshfeldJWJr2007Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing CommitteeCirculation2008117226129518079354
   PubMedGoogle Scholar
• Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Antiplatelet Trialists’ CollaborationBMJ19943086921811068298418
   PubMed Web of Science ®Google Scholar
• FrelingerAL3rdFurmanMILindenMDResidual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistanceCirculation2006113252888289616785341
   PubMed Web of Science ®Google Scholar
• OhmoriTYatomiYNonakaTAspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patientsJ Thromb Haemost2006461271127816706971
   PubMed Web of Science ®Google Scholar
• GachetCRegulation of platelet functions by P2 receptorsAnnu Rev Pharmacol Toxicol20064627730016402906
   PubMed Web of Science ®Google Scholar
• GachetCP2 receptors, platelet function and pharmacological implicationsThromb Haemost200899346647218327393
   PubMed Web of Science ®Google Scholar
• GachetCADP receptors of platelets and their inhibitionThromb Haemost200186122223211487010
   PubMed Web of Science ®Google Scholar
• GachetCLéonCHechlerBThe platelet P2 receptors in arterial thrombosisBlood Cells Mol Dis200636222322716466948
   PubMed Web of Science ®Google Scholar
• HechlerBCattaneoMGachetCThe P2 receptors in platelet functionSemin Thromb Hemost200531215016115852218
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• NorgardNBAbu-FadelMFuture prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonistsRecent Pat Cardiovasc Drug Discov20083319420018991794
   PubMedGoogle Scholar
• SmallDSFaridNAPayneCDEffects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelJ Clin Pharmacol200848447548418303127
   PubMed Web of Science ®Google Scholar
• SmallDSFaridNALiYGEffect of ranitidine on the pharma-cokinetics and pharmacodynamics of prasugrel and clopidogrelCurr Med Res Opin20082482251225718786302
   PubMed Web of Science ®Google Scholar
• SaviPPereilloJMUzabiagaMFIdentification and biological activity of the active metabolite of clopidogrelThromb Haemost200084589189611127873
   PubMed Web of Science ®Google Scholar
• SaviPCombalbertJGaichCThe antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1 AThromb Haemost19947223133177831671
   PubMed Web of Science ®Google Scholar
• LinsRBroekhuysenJNecciariJDeroubaixXPharmacokinetic profile of 14C-labeled clopidogrelSemin Thromb Hemost199925Suppl 2293310440420
   PubMed Web of Science ®Google Scholar
• KuriharaA HKKazuiMIshizukaTFaridNAIkedaTIn vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in active metabolite formationDrug Metab Rev200537Suppl 299
   Google Scholar
• RehmelJLEcksteinJAFaridNAInteractions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450Drug Metab Dispos200634460060716415119
   PubMed Web of Science ®Google Scholar
• BrandtJTPayneCDWiviottSDA comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationAm Heart J2007153166.e9e1617174640
   PubMed Web of Science ®Google Scholar
• FaridNAPayneCDSmallDSCytochrome P450 3 A inhibition by ketoconazole affects prasugrel and clopidogrel pharmaco-kinetics and pharmacodynamics differentlyClin Pharmacol Ther200781573574117361128
   PubMed Web of Science ®Google Scholar
• FaridNASmithRLGillespieTAThe disposition of prasugrel, a novel thienopyridine, in humansDrug Metab Dispos20073571096110417403916
   PubMed Web of Science ®Google Scholar
• GilardMArnaudBCornilyJCInfluence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) studyJ Am Coll Cardiol200851325626018206732
   PubMed Web of Science ®Google Scholar
• LauWCGurbelPAWatkinsPBContribution of hepatic cyto-chrome P450 3 A4 metabolic activity to the phenomenon of clopidogrel resistanceCirculation2004109216617114707025
   PubMed Web of Science ®Google Scholar
• LauWGurbelPCarvilleDSaint Johns wort enhances clopi-dogrel responsiveness in clopidogrel resistant volunteers and patients by induction of CYP3A4 isoenzyme (abstr)J Am Coll Cardiol200749Suppl A343A
   Google Scholar
• FaridNAJakubowskiJPayneCDEffect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjectsCurr Med Res Opin20092581821182919530977
   PubMed Web of Science ®Google Scholar
• SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med2009360436337519106083
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome p-450 polymorphisms and response to clopidogrelN Engl J Med2009360435436219106084
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesCirculation2009119192553256019414633
   PubMed Web of Science ®Google Scholar
• VarenhorstCJamesSErlingeDGenetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery diseaseEur Heart J200930141744175219429918
   PubMed Web of Science ®Google Scholar
• BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost20075122429243617900275
   PubMed Web of Science ®Google Scholar
• FrereCCuissetTQuiliciJADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndromeThromb Haemost200798483884317938809
   PubMed Web of Science ®Google Scholar
• GeislerTLangerHWydymusMLow response to clopidogrel is associated with cardiovascular outcome after coronary stent implantationEur Heart J200627202420242517005534
   PubMed Web of Science ®Google Scholar
• HochholzerWTrenkDBestehornHPImpact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placementJ Am Coll Cardiol20064891742175017084243
   PubMed Web of Science ®Google Scholar
• BuonamiciPMarcucciRMiglioriniAImpact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosisJ Am Coll Cardiol200749242312231717572245
   PubMed Web of Science ®Google Scholar
• MalininAPokovASperglingMMonitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) studyThromb Res2007119327728416563469
   PubMed Web of Science ®Google Scholar
• van WerkumJWvan der SteltCASeesingTHHackengCMten BergJMA head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary interventionJ Thromb Haemost20064112516251816938130
   PubMed Web of Science ®Google Scholar
• von BeckerathNPogatsa-MurrayGWieczorekASibbingDSchomigAKastratiACorrelation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsivenessThromb Haemost200695591091116676093
   PubMed Web of Science ®Google Scholar
• AleilBRavanatCCazenaveJPRochouxGHeitzAGachetCFlow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseasesJ Thromb Haemost200531859215634270
   PubMed Web of Science ®Google Scholar
• VarenhorstCJamesSErlingeDAssessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirinAm Heart J20091573562.e1e919249429
   PubMed Web of Science ®Google Scholar
• JakubowskiJAPayneCDLiYGThe use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administrationThromb Haemost200899240941518278193
   PubMed Web of Science ®Google Scholar
• GeigerJTeichmannLGrossmannRMonitoring of clopidogrel action: comparison of methodsClin Chem200551695796515817818
   PubMed Web of Science ®Google Scholar
• BarraganPBouvierJLRoquebertPOResistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylationCatheter Cardiovasc Interv200359329530212822144
   PubMed Web of Science ®Google Scholar
• BonelloLPaganelliFArpin-BornetMVasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular eventsJ Thromb Haemost2007581630163617488353
   PubMed Web of Science ®Google Scholar
• BlindtRStellbrinkKde TaeyeAThe significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosisThromb Haemost20079861329133418064332
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPHiattBLO’ConnorCMClopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet reactivityCirculation2003107232908291312796140
   PubMed Web of Science ®Google Scholar
• MatetzkySShenkmanBGuettaVClopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarctionCirculation2004109253171317515184279
   PubMed Web of Science ®Google Scholar
• SnoepJDHovensMMEikenboomJCvan der BomJGJukemaJWHuismanMVClopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysisAm Heart J2007154222123117643570
   PubMed Web of Science ®Google Scholar
• MontalescotGSiderisGMeulemanCA randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trialJ Am Coll Cardiol200648593193816949482
   PubMed Web of Science ®Google Scholar
• von BeckerathNTaubertDPogatsa-MurrayGSchömigEKastratiASchömigAAbsorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) TrialCirculation2005112192946295016260639
   PubMed Web of Science ®Google Scholar
• LemesleGDelhayeCSudreAImpact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcomeAm Heart J2009157237538219185648
   PubMed Web of Science ®Google Scholar
• L’AllierPLDucrocqGPrannoNClopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized studyJ Am Coll Cardiol200851111066117218342223
   PubMed Web of Science ®Google Scholar
• CuissetTFrereCQuiliciJBenefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stentingJ Am Coll Cardiol20064871339134517010792
   PubMed Web of Science ®Google Scholar
• AngiolilloDFernández-OrtizABernardoEHigh clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variabilityEur Heart J200425211903191015522469
   PubMed Web of Science ®Google Scholar
• AngiolilloDJBernardoEPalazuelosJFunctional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized studyThromb Haemost200899116116818217149
   PubMed Web of Science ®Google Scholar
• AngiolilloDJCostaMAShoemakerSBFunctional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatmentAm J Cardiol2008101444044518312754
   PubMed Web of Science ®Google Scholar
• AsaiFJakubowskiJANaganumaHPlatelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humansPlatelets200617420921716769598
   PubMed Web of Science ®Google Scholar
• JakubowskiJAPayneCDBrandtJTThe platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjectsJ Cardiovasc Pharmacol200647337738416633079
   PubMed Web of Science ®Google Scholar
• MatsushimaNJakubowskiJAAsaiFPlatelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humansPlatelets200617421822616769599
   PubMed Web of Science ®Google Scholar
• WeerakkodyGJJakubowskiJABrandtJTComparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder statusAm J Cardiol2007100233133617631093
   PubMed Web of Science ®Google Scholar
• WeerakkodyGJJakubowskiJABrandtJTPayneCDNaganumaHWintersKJGreater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysisJ Cardiovasr Pharmacol Ther2007123205212
   PubMed Web of Science ®Google Scholar
• JakubowskiJAWintersKJNaganumaHWallentinLPrasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profileCardiovasc Drug Rev200725435737418078435
   PubMed Web of Science ®Google Scholar
• JernbergTPayneCDWintersKJPrasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEur Heart J200627101166117316621870
   PubMed Web of Science ®Google Scholar
• WiviottSDTrenkDFrelingerALPrasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialCirculation2007116252923293218056526
   PubMed Web of Science ®Google Scholar
• PayneCDLiYGSmallDSIncreased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrelJ Cardiovasc Pharmacol200750555556218030066
   PubMed Web of Science ®Google Scholar
• WallentinLVarenhorstCJamesSPrasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEur Heart J2008291213018055486
   PubMed Web of Science ®Google Scholar
• PayneCDLiYGBrandtJTSwitching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjectsPlatelets200819427528118569863
   PubMed Web of Science ®Google Scholar
• SugidachiAOgawaTKuriharaAThe greater in vivo anti-platelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metaboliteJ Thromb Haemost2007571545155117456192
   PubMed Web of Science ®Google Scholar
• ErlingeDVarenhorstCBraunOOPatients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivoJ Am Coll Cardiol200852241968197719055987
   PubMed Web of Science ®Google Scholar
• WiviottSDAntmanEMWintersKJRandomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trialCirculation2005111253366337315967851
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• AntmanEMWiviottSDMurphySAEarly and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysisJ Am Coll Cardiol200851212028203318498956
   PubMed Web of Science ®Google Scholar
• MontalescotGWiviottSDBraunwaldEPrasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialLancet2009373966572373119249633
   PubMed Web of Science ®Google Scholar
• SerebruanyVLThe FDA Prasugrel Review: Adjudication of Myocardial Infarction ControversyCardiology2009114212612919506374
   PubMed Web of Science ®Google Scholar
• O’DonoghueMAntmanEMBraunwaldEThe efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) AnalysisJ Am Coll Cardiol200954867868519679245
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEAngiolilloDJGreater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38Circulation2008118161626163618757948
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHIntensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trialLancet200837196211353136318377975
   PubMed Web of Science ®Google Scholar
• MurphySAAntmanEMWiviottSDReduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trialEur Heart J200829202473247918682445
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSPetersRJEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet2001358928152753311520521
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSZhaoFEarly and late effects of clopidogrel in patients with acute coronary syndromesCirculation2003107796697212600908
   PubMed Web of Science ®Google Scholar